{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:04:08Z","timestamp":1770822248656,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ejca.2005.12.028","type":"journal-article","created":{"date-parts":[[2006,6,19]],"date-time":"2006-06-19T13:45:15Z","timestamp":1150724715000},"page":"1520-1529","source":"Crossref","is-referenced-by-count":44,"title":["Cytogenetics and molecular cytogenetics in multiple myeloma"],"prefix":"10.1016","volume":"42","author":[{"given":"Peter","family":"Liebisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2005.12.028_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10428199909083378","article-title":"Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumour microenvironment","volume":"34","author":"Dhodapkar","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2005.12.028_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","article-title":"The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells","volume":"100","author":"Jourdan","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib4","first-page":"380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma","volume":"66","author":"Dewald","year":"1985","journal-title":"plasma cell leukaemia, or amyloidosis. Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V71.2.453.453","article-title":"Plasma cell karyotype in multiple myeloma","volume":"71","author":"Gould","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/0959-8049(93)90071-M","article-title":"Karyotype in multiple myeloma and plasma cell leukaemia","volume":"29A","author":"Weh","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib7","first-page":"41","article-title":"Waldron JA, Jagannath S, Barlogie B","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet"},{"key":"10.1016\/j.ejca.2005.12.028_bib8","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.V85.9.2490.bloodjournal8592490","article-title":"Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis","volume":"85","author":"Lai","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x","article-title":"Multiple myeloma: almost all patients are cytogenetically abnormal","volume":"94","author":"Zandecki","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2141.1997.2443061.x","article-title":"Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma","volume":"98","author":"Calasanz","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib11","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1997.15.7.2659","article-title":"Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants","volume":"15","author":"Tricot","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2005.12.028_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2005.12.028_bib13","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib14","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood.V92.11.4269","article-title":"Identification of new nonrandom translocations in multiple myeloma with multicolour spectral karyotyping","volume":"92","author":"Sawyer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K","article-title":"High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization","volume":"24","author":"Avet-Loiseau","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib16","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V91.8.3007.3007_3007_3010","article-title":"Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization","volume":"91","author":"Cigudosa","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib17","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood.V92.8.2997","article-title":"Detection of nonrandom chromosomal changes in multiple myeloma by comparative genomic hybridization","volume":"92","author":"Avet-Loiseau","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<104::AID-GCC5>3.0.CO;2-C","article-title":"Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma","volume":"25","author":"Aalto","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2141.2003.04417.x","article-title":"Value of Comparative Genomic Hybridization (CGH) and Fluorescence in situ Hybridization (FISH) for molecular diagnostics in multiple myeloma","volume":"122","author":"Liebisch","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib20","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Gutierrez","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1309\/5KWKP6UKGNXXHMYH","article-title":"Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization","volume":"122","author":"Tchinda","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2005.12.028_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I","article-title":"Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances","volume":"20","author":"Solinas-Toldo","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib23","first-page":"150","article-title":"Automated screening for genomic imbalances in multiple myeloma using microarray-based comparative genomic hybridization (M-CGH)","volume":"90","author":"Wendl","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2005.12.028_bib24","first-page":"153","article-title":"Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes","volume":"149","author":"Tabernero","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2005.12.028_bib25","first-page":"2185","article-title":"Intergroupe Francophone du Myelome","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib26","first-page":"3854","article-title":"Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.12.028_bib27","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","article-title":"Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Drach","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib29","first-page":"1271","article-title":"The t(4;14)(p16","volume":"98","author":"Fonseca","year":"2001","journal-title":"3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathies of undetermined significance. Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib30","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0165-4608(97)00058-7","article-title":"A novel three-colour, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies","volume":"101","author":"Ahmann","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ejca.2005.12.028_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1046\/j.1365-2141.2000.02488.x","article-title":"Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13","volume":"111","author":"Avet-Loiseau","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/gcc.10140","article-title":"Delineation of the minimal region of loss at 13q14 in multiple myeloma","volume":"36","author":"Elnenaei","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"P53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib37","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/sj.leu.2401609","article-title":"Analysis of p73 and p53 gene deletions in multiple myeloma","volume":"13","author":"Schultheis","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib38","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib39","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/sj.leu.2403153","article-title":"High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis","volume":"17","author":"Liebisch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib40","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib41","first-page":"4546","article-title":"14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process fo the oncogenesis of multiple myeloma Intergroupe Francophone du Myelome","volume":"59","author":"Avet-Loiseau","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.12.028_bib42","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib43","first-page":"5640","article-title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32)","volume":"58","author":"Avet-Loiseau","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.12.028_bib44","first-page":"1743","article-title":"Multicolour spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma","volume":"92","author":"Rao","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.2001.02546.x","article-title":"Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma","volume":"112","author":"Sawyer","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib46","first-page":"49","article-title":"Multicolour spectral karyotyping in multiple myeloma","volume":"113","author":"Sawyer","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ejca.2005.12.028_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJM199507063330108","article-title":"Jumping genes and the immunoglobulin V gene system","volume":"333","author":"Schwartz","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.12.028_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma:increasing evidence for a multistep transformation process","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood.V96.3.808","article-title":"The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies","volume":"96","author":"Willis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib51","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","article-title":"Mechanisms of chromosomal translocations in B cell lymphomas","volume":"20","author":"K\u00fcppers","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2005.12.028_bib52","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2005.12.028_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.V90.2.526","article-title":"The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukaemia as detected by in situ hybridization","volume":"90","author":"Nishida","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib54","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2005.12.028_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-065X.2003.00052.x","article-title":"Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma","volume":"194","author":"Bergsagel","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ejca.2005.12.028_bib56","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib57","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib58","first-page":"83","volume":"35","author":"Greipp","year":"1999","journal-title":"Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2005.12.028_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cyto.990170409","article-title":"A new method for the analysis of plasma cell DNA content in mutiple myeloma samples using a CD38\/propidium iodide double staining technique","volume":"17","author":"Orfao","year":"1994","journal-title":"Cytometry"},{"key":"10.1016\/j.ejca.2005.12.028_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V55.3.403.403","article-title":"Cellular DNA content as a marker of human multiple myeloma","volume":"55","author":"Latreille","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib61","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib62","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib63","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.12.028_bib64","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gcc.10275","article-title":"Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid patients","volume":"38","author":"Smadja","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.20098","article-title":"Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma","volume":"42","author":"Liebisch","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2005.12.028_bib67","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1182\/blood-2002-06-1737","article-title":"Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development","volume":"101","author":"Zhan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib68","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","article-title":"Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts","volume":"100","author":"Tarte","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib69","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood-2003-11-3837","article-title":"Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels","volume":"104","author":"Specht","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0002-9343(86)90625-X","article-title":"Biclonal and hypodiploid multiple myeloma","volume":"80","author":"Smith","year":"1986","journal-title":"Am. J. Med"},{"key":"10.1016\/j.ejca.2005.12.028_bib71","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.1998.00657.x","article-title":"Prognostic value of cytogenetics in multiple myeloma","volume":"101","author":"Seong","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib73","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib74","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib75","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","article-title":"Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression","volume":"101","author":"Shaughnessy","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib76","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes","volume":"91","author":"Perez-Simon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib77","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib78","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum \u00df-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib79","first-page":"715","article-title":"Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (\u039413) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study","volume":"62","author":"Fonseca","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2005.12.028_bib80","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib81","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/sj.leu.2401909","article-title":"Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance","volume":"14","author":"K\u00f6nigsberg","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib82","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib83","first-page":"88","article-title":"Gains on chromosome arm 9q represent a novel and independent marker of adverse prognosis in multiple myeloma patients receiving upfront high-dose chemotherapy and autologous stem cell transplantation","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2005.12.028_bib84","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","article-title":"Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation","volume":"103","author":"Kr\u00f6ger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib85","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2005.12.028_bib86","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib88","first-page":"1015","article-title":"Mutations of the p53 gene in human myeloma cell lines","volume":"7","author":"Mazars","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2005.12.028_bib89","first-page":"758","article-title":"Inactivation of tumour suppressor genes, p53 and Rb1, in plasma cell dyscrasias","volume":"8","author":"Corradini","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2005.12.028_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","article-title":"p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy","volume":"81","author":"Neri","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib91","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.1992.tb08253.x","article-title":"Rare occurrence of p53 gene mutations in multiple myeloma","volume":"81","author":"Preudhomme","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib92","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1046\/j.1365-2141.1998.01124.x","article-title":"Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance","volume":"103","author":"Ackermann","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib93","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2005.12.028_bib94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27(Kip1) and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Haematology"},{"key":"10.1016\/j.ejca.2005.12.028_bib95","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1998.00700.x","article-title":"Multiple myeloma and the translocation t(11;14)(q13;q32) \u2013 a report on 13 cases","volume":"101","author":"Fonseca","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2005.12.028_bib96","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib97","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib98","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7","article-title":"The (11;14)(q13;q32) translocation in multiple myeloma A morphologic and immunohistochemical study","volume":"113","author":"Hoyer","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2005.12.028_bib99","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib100","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2002-08-2436","article-title":"Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants","volume":"101","author":"Avet-Loiseau","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib101","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood-2002-12-3789","article-title":"Cyclin D1 overexpression is a favourable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation","volume":"102","author":"Soverini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib102","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1182\/blood.V90.10.4062","article-title":"A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene","volume":"90","author":"Richelda","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib103","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2005.12.028_bib104","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-09-2801","article-title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript","volume":"101","author":"Santra","year":"2003","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906003169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T15:31:56Z","timestamp":1586964716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906003169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":104,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0959804906003169"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2005.12.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}